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Although the Enders strain of mumps virus (MuV) encodes a functional V protein that acts as an
interferon (IFN) antagonist, in multi-cycle growth assays MuV Enders grew poorly in naı¨ve (‘IFN-
competent’ Hep2) cells but grew to high titres in ‘IFN-compromised’ Hep2 cells. Even so, the
growth rate of MuV Enders was significantly slower in ‘IFN-compromised’ Hep2 cells when
compared with its replication rate in Vero cells and with the replication rate of parainfluenza virus
type 5 (a closely related paramyxovirus) in both naı¨ve and ‘IFN-compromised’ Hep2 cells. This
suggests that a consequence of slower growth is that the IFN system of naı¨ve Hep2 cells can
respond quickly enough to control the growth of MuV Enders. This is supported by the finding that
rapidly growing variants of MuV Enders that were selected on ‘IFN-compromised’ Hep2 cells (i.e.
in the absence of any selection pressure exerted by the IFN response) also grew to high titres on
naı¨ve Hep2 cells. Sequencing of the complete genome of one of these variants identified a single
point mutation that resulted in a substitution of a conserved asparagine by histidine at position
498 of the haemagglutinin–neuraminidase protein, although this mutation was not present in all
rapidly growing variants. These results support the concept that there is a race between the ability
of a cell to detect and respond to virus infection and the ability of a virus to block the IFN
response. Importantly, this emphasizes that factors other than viral IFN antagonists influence the
sensitivity of viruses to IFN.
INTRODUCTION
Cells respond to virus infection by secreting alpha and beta
interferons (IFN-a/b), which act in both autocrine and
paracrine fashions to upregulate the expression of hun-
dreds of cellular genes, the products of many having
antiviral functions. Cells detect the presence of viruses by
having receptors that recognize specific pathogen-
associated molecular patterns (PAMPs). PAMPs are often
viral nucleic acids, produced during the virus replication
cycle (reviewed by Randall & Goodbourn, 2008; Takeuchi
& Akira, 2009). RIG-I and mda-5 are two intracellular
detectors of viral PAMPs which recognize RNA structures
not normally present in cells, such as double-stranded RNA
(dsRNA) and/or 59-triphosphorylated, uncapped single-
stranded RNA (ssRNA) (Andrejeva et al., 2004; Yoneyama
et al., 2004; Hornung et al., 2006; Pichlmair et al., 2006;
Kato et al., 2008). When activated by their appropriate
ligands, RIG-I and mda-5 initiate a signalling cascade that
ultimately leads to the synthesis of IFN-a/b. Secreted IFN-
a/b binds to the IFN-a/b receptor and activates JAK1 and
Tyk2, two kinases associated with the cytoplasmic domain
of the receptor. These in turn phosphorylate the latent
cytoplasmic transcription factors STAT1 and STAT2,
which then form stable heterodimers and associate with
IRF-9 to create the ISGF3 transcription factor complex that
activates IFN-a/b responsive genes (reviewed by Platanias,
2005; Randall & Goodbourn, 2008).
Many of the genes upregulated by IFN encode proteins that
have either direct or indirect antiviral activities that can
limit virus replication. Although their antiviral activities
are often restricted to specific viruses or virus families,
there are examples of IFN-inducible antiviral proteins that
act at most stages of the growth cycle of viruses, from entry
and uncoating (e.g. Trim5a), to viral replication and
transcription (e.g. Mx), viral protein synthesis (e.g. PKR
and oligo A synthetase) and virus egress (e.g. viperin and
tetherin) (reviewed by Randall & Goodbourn, 2008).
However, viruses can still replicate and cause disease in
vivo because they encode products, usually proteins, which
interfere with some aspect of the IFN response.
Nevertheless, viruses are usually incapable of completely
circumventing the IFN response, which remains critical in
restricting virus replication during the initial stages of virus
infection prior to development of adaptive immune3These authors contributed equally to this work.
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responses. Over the last few years, a great deal has been
learnt about the mechanisms of action of many viral IFN
antagonists (reviewed by Haller et al., 2006; Randall &
Goodbourn, 2008). Loss of function of viral IFN
antagonists sensitizes viruses to the IFN response, such
that the viruses cannot replicate in IFN-competent cells
and are non-pathogenic in IFN-competent animals.
However, such viruses usually replicate well in IFN-
compromised cells and remain pathogenic in IFN-com-
promised animals. Although the critical importance of viral
IFN antagonists in facilitating virus replication in IFN-
competent cells is without dispute, it is not clear whether
other virus–host interactions can influence the sensitivity
of viruses to the IFN response.
Mumps virus (MuV) is a rubulavirus within the family
Paramyxoviridae, a group of negative-sense ssRNA viruses
(reviewed by Lamb & Parks, 2006). Like other rubula-
viruses, MuV encodes an IFN antagonist termed the V
protein. As with its close relative parainfluenza virus type 5
(PIV5; formerly known as SV5; Chatziandreou et al., 2004),
the V protein of MuV targets STAT1 for proteasome-
mediated degradation, thereby blocking IFN signalling
(Didcock et al., 1999; Kubota et al., 2001; Nishio et al.,
2002; Yokosawa et al., 2002). MuV V protein also targets
STAT3 for degradation, but it is unclear what biological
role this plays during infection (Ulane et al., 2003). This V
function is separate from its role in STAT1 degradation
(Puri et al., 2009). In addition, the V proteins of MuV,
PIV5 and most other paramyxoviruses can help limit IFN
production by binding and inhibiting mda-5 (Andrejeva
et al., 2004; Childs et al., 2007). Mumps is a serious human
illness whose symptoms often include meningitis.
Consequently, vaccination against MuV is routine
(Plotkin, 2004). The Enders strain of MuV was isolated
in 1945 (Enders et al., 1946) and has subsequently been
widely used for laboratory studies on MuV. In a neonatal
hamster model (used to compare the pathogenicity of
different MuV isolates), MuV Enders is highly attenuated
in comparison with wild-type viruses (McCarthy et al.,
1980). Here, we report that the Enders strain of MuV is
sensitive to the human IFN system even though it encodes
a functional IFN antagonist.
METHODS
Cells, viruses and plasmids. Vero, Hep2, 293 and A549 cells (and
derivatives) were grown as monolayers in 25 cm2 or 75 cm2 tissue
culture flasks, in Dulbecco’s modified Eagle’s medium supplemented
with 10 % (v/v) fetal calf serum at 37 uC. PIV5 (strain W3) (Choppin,
1964) and MuV Enders (Enders et al., 1946) virus stocks were grown
and titrated (in duplicate) under appropriate conditions in Vero cells.
The construction and properties of Hep2/BVDV-Npro and Hep2/
PIV5-V cells have been previously described (Hilton et al., 2006;
Carlos et al., 2007). The generation of Hep2/MuV-V cells was as
previously described for Hep2/BVDV-Npro cells. Basically, the V gene
was PCR amplified from MuV Enders-infected cells, cloned into a
modified self-inactivating, bicistronic, lentiviral expression vector
derived from pHR-SIN-CSGW (Demaison et al., 2002), and used to
generate recombinant lentivirus particles that were used to select for
cells that express V5-tagged MuV-V as previously described (Hilton
et al., 2006).
Selection of MuV Enders on naı¨ve Hep2 and Hep2/BVDV-Npro
cells. Naı¨ve Hep2 cells were infected at an m.o.i. of 1 p.f.u. per cell
and after inoculation, the infected monolayer was trypsinized and
cells were seeded into fresh flasks with a 10-fold excess of uninfected
naı¨ve Hep2 cells. After stationary incubation overnight at 37 uC,
confluent monolayers were incubated on a rocker for a further 1–
2 days. Cells were trypsinized and reseeded with a further 10-fold (for
the first three passages) or 100-fold (for a further two passages) excess
of uninfected naı¨ve Hep2 cells and incubated as above. Four days after
the fifth passage, the medium was harvested, titrated and used to
inoculate Vero monolayers in 96-well plates at an m.o.i. of 0.1 p.f.u.
per well. At 7–8 days after infection, medium was harvested from 30
wells that showed a cytopathic effect, and these were termed MuV
Enders clone 3 subclones 1–30.
A selection of MuV Enders was made in naı¨ve and BVDV-Npro-
expressing Hep2 cells which followed basically the same regime as
above (using MuV Enders clone 3 to inoculate, but diluting
infected : uninfected cells 1 : 100 at every passage) for four passages.
Two days after the fourth passage, medium was harvested and the
amount of infectious virus was titrated by plaque assay.
Immunoprecipitation, immunoblotting and immunofluores-
cence. The procedures for immunoblotting, immunofluorescence
and immunoprecipitation have been described previously (Randall &
Dinwoodie, 1986; Carlos et al., 2005). Antibodies used in these
procedures included monoclonal antibodies (mAbs) to the V5-tag
(Hanke et al., 1992; Serotec, MCA1360), and polyclonal antibodies to
STAT1 (Santa Cruz, sc-417), STAT3 (Abcam, ab2984) and b-actin
(Sigma, A5441).
Sequencing. Naı¨ve Hep2 cells were infected at an m.o.i. of 0.1 p.f.u.
per cell. Two days post-infection, total RNA was prepared using
TRIzol reagent (Invitrogen, 15596). RT-PCR was performed using
superscript III one-step RT-PCR kit (Invitrogen, 12574) and gene-
specific primers spanning the complete MuV genome (primer
sequences are available on request). RT-PCR products were purified
using GenElute PCR clean-up kit (Sigma, NA1020) and sequencing
reactions were performed using Big Dye Terminator v3.1 cycle
sequencing kit (Applied Biosystems, 4336917).
RESULTS
The Enders strain of MuV does not grow
efficiently in IFN-competent Hep2 cells but grows
to high titres in IFN-compromised Hep2 cells
Whilst comparing the replication of a number of viruses in
cells that can or cannot produce and respond to IFN, we
noted that, unlike the closely related virus PIV5, the Enders
strain of MuV did not replicate well in naı¨ve Hep2 cells
that can produce and respond to IFN (Fig. 1). However,
MuV Enders grew to high titres in Hep2 cells engineered to
be either unresponsive to IFN (Hep2/PIV5-V cells; Young
et al., 2003) or unproductive for IFN (Hep2/BVDV-Npro;
Hilton et al., 2006; Carlos et al., 2007), illustrating that
MuV is sensitive to the IFN response of Hep2 cells (Fig. 1).
However, even in these ‘IFN-compromised’ Hep2 cells,
MuV Enders had delayed growth kinetics since following a
low m.o.i., the virus reached titres of 106–107 p.f.u. ml21 at
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4–6 days post-infection (p.i.), whereas in Vero cells
[monkey cells which do not produce IFN due to
spontaneous gene deletions (Desmyter et al., 1968; Mosca
& Pitha, 1986)], it had reached titres of 107 p.f.u. ml21 by 2
days p.i. Also in contrast with MuV Enders, PIV5 reached
titres of 107–108 p.f.u. ml21 in both ‘IFN-competent’ and
‘IFN-compromised’ Hep2 cells by 2 days p.i. (Fig. 1).
MuV Enders V protein targets STAT1 and STAT3
for degradation and interacts with mda-5
One obvious explanation as to why MuV Enders replicated
efficiently in ‘IFN-compromised’ Hep2 cells but poorly in
naı¨ve ‘IFN-competent’ Hep2 cells could have been that it
did not encode a functional V protein. We therefore
examined whether MuV Enders blocked IFN-signalling and
whether the V protein interacted with mda-5. Hep2 cells
were infected with MuV Enders prior to treatment with
IFN, and the levels of STAT1 (which is inducible by IFN)
and STAT3 were estimated by immunoblot analysis.
Uninfected cells treated with IFN were used as a control.
STAT1 was clearly degraded by MuV Enders in untreated
cells by 8 h p.i. and the high levels of STAT1 in IFN-
pretreated cells were significantly reduced by 24 h p.i.
(Fig. 2a), consistent with previously published work that
has shown that the V protein of MuV targets STAT1 for
proteasome-mediated degradation (Ulane et al., 2003).
Interestingly, whilst STAT3 was also degraded in untreated
cells (in agreement with data from Ulane et al., 2003) and
although its expression is not induced by IFN, there was no
evidence of STAT3 degradation at 8 h p.i. in IFN-
pretreated cells, although some degradation of STAT3
was observed at 24 h p.i. Whilst the reasons for this remain
unclear, it suggests that IFN-pretreatment is somehow
affecting the efficiency of degradation of STAT3. Next, the
MuV Enders V gene was cloned into a derivative of the
plasmid pHR-SIN-CSGW that can be used either in
Fig. 1. Multiple-step growth analysis of MuV Enders (a) and PIV5
(b). Vero cells, naı¨ve Hep2 cells (Hep2n) and Hep2 cells that
constitutively express either PIV5-V protein (which are unable to
respond to IFN) or BVDV-Npro (which cannot produce IFN) were
infected at an m.o.i. of 0.01 p.f.u. per cell, and the amount of
infectious virus in the culture medium was titrated at 2, 4 and
6 days p.i. Note: similar experiments were carried out on multiple
occasions and the results shown are representative of a typical
experiment.
Fig. 2. MuV Enders V protein targets STAT1 and STAT3 for
degradation and interacts with mda-5. (a) Naı¨ve Hep2 cells were
infected with MuV Enders for 8 h, or mock infected, prior to
addition of IFN-a [Roferon A (Roche) 1000 IU ml”1] to the culture
medium. At 8 and 24 h p.i., cells were harvested and the presence
of STAT1 and STAT3 was detected by immunoblot analysis. b-
Actin acted as a loading control. (b) 293 cells were transfected
with a control plasmid (empty vector) or plasmids expressing V5-
tagged V proteins of MuV Enders or JL5, which has previously
been shown to bind mda-5 (Andrejeva et al., 2004; Childs et al.,
2007), together with a plasmid that expresses the FLAG-tagged
helicase domain of mda-5. At 48 h post-transfection, the V
proteins were immunoprecipitated and the presence of the mda-
5 helicase domain was detected by immunoblot analysis.
Immunoglobulin heavy chain (IgH) was also detected in the
immunoblot.
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transient transfections for expression of the gene of interest
or to generate appropriate lentivirus vectors (Demaison et
al., 2002). 293 cells were co-transfected with plasmids
expressing the FLAG-tagged helicase domain of mda-5
together with a plasmid expressing V5-tagged V protein
from MuV Enders, or with a control plasmid. The V
protein was immunoprecipitated with anti-V5 antibody
and the immunoprecipitates were blotted for FLAG-tagged
mda-5. The mda-5 helicase domain co-precipitated with
the V protein of MuV Enders (Fig. 2b). We next engineered
a Hep2 cell line to constitutively express the MuV Enders V
protein. As expected, STAT1 could not be detected in these
cells even following treatment with IFN for 24 h (Fig. 3a).
Furthermore, they supported the replication of a number
of IFN-sensitive viruses, including a recombinant
Bunyamwera virus with a deletion in its NSs gene
(Fig. 3b), as well as MuV Enders (Fig. 3c).
MuV Enders variants that grow to high titres in
naı¨ve Hep2 cells do not have alterations in their V
gene
Although the MuV V protein inhibited IFN signalling and
interacted with mda-5, it remained possible that to adapt
to grow in naı¨ve Hep2 cells, MuV Enders might need to
improve/alter in some manner the efficacy by which its V
protein acts as an IFN antagonist. To test this, variants of
MuV Enders that replicated to high titres in ‘IFN-
competent’ Hep2 cells were isolated and the V genes of
these variants were sequenced. These variants were
isolated by infecting naı¨ve Hep2 cells with MuV Enders
at an m.o.i. of ~1 p.f.u. per cell and every 2–3 days the
infected cells were passaged together with a 10-fold
(passages 1–3) or 100-fold (passages 4 and 5) excess of
uninfected naı¨ve Hep2 cells. Four days after the fifth
passage, virus released into the medium was subcloned on
Vero cells and 30 subclones were isolated. Low m.o.i.
growth curves of a number of these clones were performed
on naı¨ve Hep2, Hep2/BVDV-Npro and Hep2/PIV5-V
cells. Unlike the parental MuV, these variants replicated to
high titres in naı¨ve Hep2 cells, reaching a final titre of
~106 p.f.u. ml21. All subclones had similar growth curves,
although only those of cl3/30 are shown as an example
(Fig. 4).
To determine whether the ability of these selected
subclones to grow in ‘IFN-competent’ Hep2 cells was due
to mutations in their V proteins, the V genes of five
subclones (including cl3/30) were cloned and sequenced.
No changes resulting in amino acid substitutions were
observed in the V gene sequences.
Whole genome sequencing of MuV Enders cl3/30
reveals it has a single mutation in its HN gene
To determine the genetic basis of the adaptation to growth
in Hep2 cells, the complete genomes of MuV Enders and
the variant cl3/30 were sequenced. The sequence of cl3/30
Fig. 3. Characterization of Hep2 cells that constitutively express
the V protein of MuV Enders. (a) STAT1 is degraded in cells that
constitutively express MuV-V. Naı¨ve Hep2, Hep2/BVDV-Npro and
Hep2/MuV-V cells were or were not treated with IFN-a [Roferon A
(Roche) 1000 IU ml”1] for 18 h and STAT1 was detected by
immunoblot analysis. BVDV-Npro and MuV-V had N-terminal or C-
terminal V5 tags, respectively, and their presence was detected by
an anti-V5 tag antibody; b-actin acted as a loading control. (b)
Unlike wild-type Bunyamwera virus (BUNV wt), which forms
plaques in naı¨ve Hep2, Hep2/MuV-V and Hep2/BVDV cells, a
recombinant Bunyamwera virus that does not encode the NSs
protein, termed rBUNVDNSs, does not form plaques in naı¨ve Hep2
cells but does plaque Hep2/MuV-V and Hep2/BVDV cells.
Plaques shown are 4 days p.i. (c) The ability of naı¨ve Hep2,
Hep2/MuV-V, Hep2/PIV5-V and Hep2/BVDV-Npro cells to
support the replication of MuV was compared. Cells were infected
at an m.o.i. of 0.01 p.f.u. per cell and the amount of infectious virus
in the culture medium was titrated at 2, 4, 6 and 8 days p.i. (light,
medium and dark grey, and black, respectively).
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differed from MuV Enders at a single position (Fig. 5).
Adenine at nt 8105 was mutated to cytosine, resulting in a
change from asparagine to histidine at amino acid 498 of
the HN protein. To determine if this was a dominant
mutation in the population of viruses (bulk stock) that had
been initially selected by passaging through Hep2 cells
prior to subcloning on Vero cells (see above), RT-PCR and
consensus sequencing of this region were performed on the
bulk stock. Interestingly a double peak composed of A and
C was observed at nt 8105, indicating a mixed population
of both mutated and wild-type genomes. The two peaks
were of equal height on the electrochromatogram,
indicating that a significant proportion of viruses within
the initial selected population of viruses contained the HN
N498H mutation. However, it was also clear that not all
viruses within the initial selected bulk population con-
tained the asparagine to histidine substitution at amino
acid 498 of the HN protein, raising the possibility that
other unidentified mutations also enhance MuV Enders
replication in naı¨ve Hep2 cells.
Variants of MuV Enders that replicate to high
titres in naı¨ve Hep2 cells can be isolated by
selecting for rapidly growing viruses in IFN-
compromised Hep2 cells
Further comparison of the growth curves of cl3/30 revealed
that it (and the other subclones tested) grew more rapidly
in both Hep2/BVDV-Npro and Hep2/PIV5-V cells than
the parental virus (Fig. 4). Thus, whilst in Hep2/BVDV-
Npro cells, cl3/30 had reached a titre of ~105 p.f.u. ml21 by
2 days p.i. and 108 p.f.u. ml21 by 4 days p.i., the parental
virus had only reached titres of 103 and 106 p.f.u. ml21 by 2
and 4 days p.i., respectively. To investigate whether the
growth kinetics of MuV Enders influence its sensitivity to
the IFN response further, we tested whether variants of
MuV Enders that had been selected because they grew
Fig. 5. Electrochromatograms showing position 8105 in the Enders strain, the passaged cl3/30 virus and the Enders cl3 bulk.
Cells were infected with the viruses, total RNA was prepared and RT-PCR was used to produce amplicons that represented the
complete genome. A single coding AAC mutation was identified in the ORF of the Enders cl3/30 HN protein (HN N498H).
Consensus sequencing of the bulk from which the clones were isolated indicated that this contained a mixed population. Red, T;
green, A; blue, C; black, G.
Fig. 4. Variants of MuV Enders selected for growth on naı¨ve Hep2
cells replicate faster both in naı¨ve Hep2 cells and in Hep2 cells
expressing PIV5-V or BVDV-Npro. The listed cells were infected at
an m.o.i. of 0.01 p.f.u. per cell with either MuV Enders (a) or a
subclone (cl3/30) thereof that was derived by continuous passage
of MuV Enders through naı¨ve Hep2 cells (see Methods) (b). The
amount of infectious virus present in the culture supernatant was
titrated at 2, 4 and 6 days p.i.
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rapidly in Hep2/BVDV-Npro cells (i.e. without the
selective pressure of IFN) would also be able to propagate
in naı¨ve Hep2 cells. A similar selection procedure (as
previously described for the selection of cl3/30) was
undertaken in both naı¨ve Hep2 and Hep2/BVDV-Npro
cells since during this procedure rapidly replicating viruses
would have a significant advantage and would therefore be
selected. As predicted, selected viruses grew faster in Hep2/
BVDV-Npro cells than the parental MuV Enders (Fig. 6).
Thus, whilst the titre of the parental virus on Hep2/BVDV-
Npro cells was only 46102 p.f.u. ml21 at 1 day p.i., the
titre of the variants (selected on Hep2/BVDV-Npro cells)
was 56104 p.f.u. ml21, and at 2 days p.i. the titres were
26105 p.f.u. ml21 and 46107 p.f.u. ml21, respectively.
Furthermore, these rapidly growing variants also replicated
to high titres in naı¨ve Hep2 cells (Fig. 6). RT-PCR and
consensus sequencing of the HN gene, covering amino
acids 436–583, was undertaken on the rapidly growing
viruses selected on Hep2/BVDV-Npro cells to determine
whether the asparagine to histidine substitution at amino
acid 498 of the HN protein had occurred. However, this
mutation was not identified, confirming that other, as-yet
unidentified, mutations can also enhance virus replication
sufficiently to allow MuV Enders to replicate in naı¨ve Hep2
cells.
DISCUSSION
We have shown that although MuV Enders encodes a
functional V protein that targets STAT1 for degradation
and interacts with mda-5, MuV Enders does not grow well
in naı¨ve Hep2 cells but will replicate to high titres (106–107
p.f.u. ml21) in ‘IFN-compromised’ Hep2 cells. However,
even in ‘IFN-compromised’ Hep2 cells, the propagation of
MuV Enders is significantly slower than in Vero cells or
when compared with the replication rate of PIV5 in ‘IFN-
compromised’ Hep2 cells. This proves that although the
host cell restriction that slows the growth rate of MuV
Enders in Hep2 cells is independent of the IFN response, a
consequence of that slower growth rate was that it enabled
the IFN response of Hep2 cells to inhibit the growth of
MuV Enders in multi-cycle growth assays. This conclusion
is supported by the fact that variants of MuV Enders
selected by passage through naı¨ve Hep2 cells replicated
more rapidly than MuV Enders in ‘IFN-compromised’
Hep2 cells. To test directly whether viral growth kinetics
could influence the sensitivity of MuV to the IFN response,
we isolated variants of MuV Enders that could grow rapidly
in ‘IFN-compromised’ Hep2 cells and then examined the
replication of these viruses in naı¨ve Hep2 cells. As
predicted, these variant viruses with faster growth rates
now replicated to high titres in naı¨ve Hep2 cells, even
though they had been selected in the absence of any
selective pressure exerted by the IFN response, highlighting
the usefulness of such a forward genetics approach.
Importantly, this also supports the idea that there is a race
between the ability of cells to detect and respond to virus
infections and the ability of a virus to block the IFN
response (Randall & Goodbourn, 2008).
Work on other viruses also suggests that factors other than
the property of the viral IFN antagonists can influence
whether viruses can replicate in ‘IFN-competent’ cells
(Young et al., 2003). Thus, it is clearly important for
viruses to control their production of PAMPs during their
replication cycle. For example, it has been reported that
although the C protein of measles virus (MeV) has no
intrinsic activity that blocks the IFN induction pathway, it
acts as a regulator of viral RNA synthesis, thereby acting
indirectly to suppress IFN induction, and hence influences
the sensitivity of MeV to the IFN system (Nakatsu et al.,
2008). Similarly, work on PIV5 has also suggested that in
order to limit IFN production, viruses must control the
balance of their transcription and replication in order to
limit the levels or types of RNA that induce the production
of IFN (Dillon & Parks, 2007; Timani et al., 2008). Results
presented here on whole-genome sequencing of one variant
(cl3/30) of MuV Enders that could replicate in naı¨ve Hep2
cells revealed that it differed from the parental strain at a
single strictly conserved position in the HN gene in a highly
conserved region of the protein. As this was the only
change in the entire genome, it is reasonable to assume that
this mutation is responsible for the more rapid growth rate
of cl3/30, and thus suggests that the entry and egress of
viruses may also (indirectly) influence their sensitivity to
the IFN response. However, it should also be noted that
sequence analysis of the bulk population of viruses selected
on naı¨ve Hep2 cells prior to subcloning revealed that not
all the viruses had the asparagine to histidine substitution
at amino acid 498 of the HN protein. Furthermore, this
mutation was not identified in rapidly growing viruses
selected on Hep2/BVDV-Npro cells, confirming that other,
Fig. 6. Variants of MuV Enders that replicate in naı¨ve Hep2 cells
can be isolated by selecting for rapidly replicating viruses in Hep2
cells expressing BVDV-Npro. Naı¨ve Hep2 or Hep2/BVDV-Npro
cells were infected with MuV Enders (a) or with virus that had been
selected on naı¨ve Hep2 cells (b) or on Hep2/BVDV-Npro cells
(see Methods) (c) at an m.o.i. of 0.01 p.f.u. per cell. The amount of
infectious virus present in the culture supernatant was titrated at 1,
2 and 4 days p.i. (light grey, dark grey and black bars, respectively).
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as yet unidentified, mutations can also enhance the speed
of replication of MuV Enders sufficiently for it to be able to
replicate in naı¨ve Hep2 cells. Quasi-species compositions of
viral populations that are not tractable by consensus
sequencing of RT-PCR products have been identified as
virulence determinants in foot and mouth disease virus
(Sanz-Ramos et al., 2008), further complicating interpreta-
tions of the meaning of single nucleotide changes in RNA
viruses. Hence, we are currently developing reverse genetics
for MuV Enders in order to address fundamental questions
as to the underlying molecular reasons why MuV Enders
grows poorly in Hep2 cells. In general, it will be of interest
to ascertain whether mutations that slow the growth cycle
of viruses at any point from virus entry to exit can sensitize
them to the IFN response. If this is the case, it cannot be
concluded that viruses (wild-type or mutant) that cannot
grow in ‘IFN-competent’ cells or animals but can replicate
in ‘IFN-compromised’ derivatives must have a defect in
their IFN antagonists. In this regard, it is of note that
insertion of the ORF of enhanced green fluorescent protein
into the major component of the viral RNA-dependent
RNA polymerase of measles virus, rinderpest virus and
canine distemper virus reduces the replication rate of these
viruses to such a degree that they are unable to overcome
the host’s antiviral defences mechanisms and are thus
attenuated in vivo (Brown et al., 2005; Plumet et al., 2005;
Silin et al., 2007). Furthermore, it has been reported that
for influenza A viruses to be highly pathogenic in Mx1-
positive strains of mice, as well as encoding a functional
IFN antagonist, they also need to have a very rapid
replication rate in order to out-compete the antiviral
response of the host (Grimm et al., 2007). An understand-
ing of the factors that influence the growth rates of viruses,
and the effects these factors have on the sensitivity of
viruses to the IFN system, will be important in order to
appreciate virus tropism and pathogenicity fully.
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